{"id":54026,"date":"2023-02-16T22:05:29","date_gmt":"2023-02-16T21:05:29","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\/"},"modified":"2023-02-16T22:05:29","modified_gmt":"2023-02-16T21:05:29","slug":"xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\/","title":{"rendered":"Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023"},"content":{"rendered":"
\n

MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter and full year 2022 after the market closes on Thursday, February 23, 2023.\n<\/p>\n

<\/a><\/p>\n

\nXencor management will host a conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.\n<\/p>\n

\nThe live webcast will be available under “Events & Presentations” in the Investors section of the Company’s website located at investors.xencor.com<\/a> and will be archived for at least 30 days. Active participants in the conference call may receive credentials for telephone access by registering at the following link: https:\/\/register.vevent.com\/register\/BI70c60751330540e3909534dca3801239<\/a>.\n<\/p>\n

\nAbout Xencor, Inc.<\/b>\n<\/p>\n

\nXencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor’s XmAb\u00ae<\/sup> technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor’s XmAb engineering technology enables small changes to a proteins structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nCharles Liles
\n
cliles@xencor.com<\/a>
626-737-8118\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter and full year 2022 after the market closes on Thursday, February 23, 2023. Xencor management will host a conference call the … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54026","6":"format-standard","7":"category-industry"},"yoast_head":"\nXencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter and full year 2022 after the market closes on Thursday, February 23, 2023. Xencor management will host a conference call the ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-16T21:05:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230216005743\/en\/1222964\/21\/Xencor_logo_BW.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023\",\"datePublished\":\"2023-02-16T21:05:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\\\/\"},\"wordCount\":231,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230216005743\\\/en\\\/1222964\\\/21\\\/Xencor_logo_BW.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\\\/\",\"name\":\"Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230216005743\\\/en\\\/1222964\\\/21\\\/Xencor_logo_BW.jpg\",\"datePublished\":\"2023-02-16T21:05:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230216005743\\\/en\\\/1222964\\\/21\\\/Xencor_logo_BW.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230216005743\\\/en\\\/1222964\\\/21\\\/Xencor_logo_BW.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\/","og_locale":"en_US","og_type":"article","og_title":"Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023 - Pharma Trend","og_description":"MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter and full year 2022 after the market closes on Thursday, February 23, 2023. Xencor management will host a conference call the ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-16T21:05:29+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230216005743\/en\/1222964\/21\/Xencor_logo_BW.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023","datePublished":"2023-02-16T21:05:29+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\/"},"wordCount":231,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230216005743\/en\/1222964\/21\/Xencor_logo_BW.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\/","url":"https:\/\/pharma-trend.com\/en\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\/","name":"Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230216005743\/en\/1222964\/21\/Xencor_logo_BW.jpg","datePublished":"2023-02-16T21:05:29+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230216005743\/en\/1222964\/21\/Xencor_logo_BW.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230216005743\/en\/1222964\/21\/Xencor_logo_BW.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/xencor-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54026","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54026"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54026\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54026"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54026"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54026"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}